Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJun 26, 2026
DataAggregated Company Financials
Companies54
  • 7D-2.3%
  • 3M20.9%
  • 1Y49.9%
  • YTD-2.6%

Over the last 7 days, the Pharma industry has dropped 2.7%, driven by a pullback from Curaleaf Holdings of 4.1%. In contrast, Apotex Health has gained 5.7%. Over the past 12 months, the industry was up 49%. As for the next few years, earnings are expected to grow by 15% per annum.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Jun 2026CA$13.5bCA$10.7b-CA$1,734,870,319.888.7x-7.8x1.3x
Sun, 24 May 2026CA$15.8bCA$12.1b-CA$1,903,880,305.828.2x-8.3x1.3x
Tue, 21 Apr 2026CA$14.9bCA$11.2b-CA$1,665,172,327.1815x-8.9x1.3x
Thu, 19 Mar 2026CA$13.9bCA$11.2b-CA$1,704,262,117.6812x-8.1x1.2x
Sat, 14 Feb 2026CA$14.0bCA$11.2b-CA$1,896,001,985.4914.9x-7.4x1.2x
Mon, 12 Jan 2026CA$16.6bCA$11.3b-CA$1,960,493,268.1216.8x-8.5x1.5x
Wed, 10 Dec 2025CA$14.2bCA$11.3b-CA$1,919,487,959.6014.3x-7.4x1.3x
Fri, 07 Nov 2025CA$15.5bCA$11.3b-CA$1,961,915,984.3520.9x-7.9x1.4x
Sun, 05 Oct 2025CA$17.7bCA$11.2b-CA$2,035,047,739.0438.3x-8.7x1.6x
Tue, 02 Sep 2025CA$18.3bCA$11.8b-CA$2,513,210,106.8339.9x-7.3x1.6x
Thu, 31 Jul 2025CA$11.4bCA$11.8b-CA$2,577,264,997.9616.8x-4.4x1x
Sat, 28 Jun 2025CA$9.8bCA$11.7b-CA$2,527,033,876.7917x-3.9x0.8x
Mon, 26 May 2025CA$23.4bCA$11.8b-CA$2,387,256,957.2817.5x-9.8x2x
Wed, 23 Apr 2025CA$9.3bCA$12.0b-CA$2,547,744,260.0918x-3.6x0.8x
Fri, 21 Mar 2025CA$10.7bCA$12.3b-CA$2,568,108,899.1620.5x-4.2x0.9x
Sun, 16 Feb 2025CA$12.3bCA$12.0b-CA$2,211,219,127.6723.8x-5.5x1x
Tue, 14 Jan 2025CA$12.4bCA$12.1b-CA$2,414,302,108.7829.5x-5.1x1x
Thu, 12 Dec 2024CA$13.4bCA$12.0b-CA$2,580,876,800.9322.8x-5.2x1.1x
Sat, 09 Nov 2024CA$15.3bCA$11.8b-CA$2,824,151,096.8817x-5.4x1.3x
Mon, 07 Oct 2024CA$18.5bCA$11.6b-CA$2,680,110,287.2427.4x-6.9x1.6x
Wed, 04 Sep 2024CA$17.1bCA$11.6b-CA$2,698,394,719.6520.4x-6.4x1.5x
Fri, 02 Aug 2024CA$20.1bCA$11.8b-CA$3,214,935,893.1119.2x-6.3x1.7x
Sun, 30 Jun 2024CA$19.5bCA$11.8b-CA$3,238,008,205.1918.5x-6x1.7x
Tue, 28 May 2024CA$21.8bCA$11.9b-CA$3,485,901,892.3912.9x-6.3x1.8x
Thu, 25 Apr 2024CA$22.9bCA$11.9b-CA$3,467,615,833.818.4x-6.6x1.9x
Sat, 23 Mar 2024CA$24.4bCA$11.9b-CA$3,467,644,851.589.5x-7x2.1x
Mon, 19 Feb 2024CA$22.3bCA$12.0b-CA$4,643,369,369.3410.4x-4.8x1.9x
Wed, 17 Jan 2024CA$21.8bCA$12.4b-CA$6,762,852,699.009.3x-3.2x1.8x
Fri, 15 Dec 2023CA$17.4bCA$12.3b-CA$6,740,875,315.008.3x-2.6x1.4x
Sun, 12 Nov 2023CA$17.2bCA$12.4b-CA$6,713,342,664.008.2x-2.6x1.4x
Tue, 10 Oct 2023CA$18.6bCA$12.4b-CA$7,334,633,773.0015x-2.5x1.5x
Thu, 07 Sep 2023CA$20.2bCA$13.0b-CA$7,921,598,042.0013.5x-2.5x1.5x
Sat, 05 Aug 2023CA$15.2bCA$13.3b-CA$9,750,894,441.0011.9x-1.6x1.1x
Mon, 03 Jul 2023CA$14.8bCA$13.2b-CA$9,514,993,610.0011.4x-1.6x1.1x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$14.8bTotal Earnings: -CA$9,514,993,610.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.6% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-0.90%
Healthcare0.34%
Pharma-2.33%
Pharma-2.33%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$31.025.7%
+CA$383.9m		n/aPE19x
CPH Cipher PharmaceuticalsCA$16.723.3%
+CA$13.7m		30.0%PE9.7x
CRON Cronos GroupCA$3.880.8%
+CA$11.2m		48.7%PS6.4x
VRNO Verano HoldingsCA$8.081.6%
+CA$9.5m		148.6%PS0.5x
CL Cresco LabsCA$1.171.7%
+CA$7.4m		67.1%PS0.5x

Latest News

CL
CA$1.17
Cresco Labs
7D
1.7%
1Y
67.1%
VRNO
CA$8.08
Verano Holdings
7D
1.6%
1Y
148.6%
CURA
CA$13.63
Curaleaf Holdings
7D
-4.1%
1Y
295.1%
Narrative Update • Jun 24

CURA: Governance Restructuring And Share Repurchases Will Support Future Earnings Power

Analysts have lifted their price target on Curaleaf Holdings by CA$1, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E based on the latest research. What’s in the News for Curaleaf Holdings Shareholders approved an amendment to Curaleaf Holdings' multiple voting shares held by CEO and Chairman Boris Jordan, removing the automatic conversion trigger that was previously linked to a U.S. listing of the Subordinate Voting Shares.
CPH
CA$16.72
Cipher Pharmaceuticals
7D
3.3%
1Y
30.0%
Narrative Update • Jun 23

CPH: Share Repurchases And Higher Margins Will Support Future Upside

Analysts have nudged their fair value estimate for Cipher Pharmaceuticals higher, lifting the implied price target from CA$21.00 to about CA$22.25. This reflects updated assumptions around revenue growth, profit margins and future P/E expectations.
ACB
CA$3.93
Aurora Cannabis
7D
-5.3%
1Y
-32.1%
Narrative Update • Jun 23

ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus

Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.
EPIC
CA$0.085
1CM
7D
-37.0%
1Y
-60.5%
APTX
CA$31.02
Apotex Health
7D
5.7%
1Y
n/a
Analysis Article • Jun 20

Apotex Health (TSX:APTX) Stock Could Be 51.7% Below Fair Value After Its IPO

IPO, early trading moves and why Apotex Health is suddenly in focus Apotex Health (TSX:APTX) has quickly drawn investor attention after completing a roughly CA$1.5b IPO at CA$24 per share, with early trading marked by share price swings and debate over what the new listing is worth. The offering combined a treasury sale of new shares with a secondary sale by existing holders. This structure put fresh capital on the company’s balance sheet while giving SK Capital Partners and other...
HITI
CA$3.12
High Tide
7D
-4.6%
1Y
0%
WEED
CA$1.31
Canopy Growth
7D
-3.7%
1Y
-23.8%
Narrative Update • Jun 18

WEED: German Medical Relaunch Will Drive Future Upside For The Stock

Analysts have trimmed their fair value estimate for Canopy Growth to CA$2.33 from CA$2.38, citing updated assumptions around revenue growth, profit margins and the future P/E they apply to the stock. What's in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical market, introducing three cannabis strains developed by its wholly owned subsidiary MTL Cannabis Corp., with plans for up to five MTL-derived strains in June 2026 and further portfolio expansion through the year.
VREO
CA$14.06
Vireo Growth
7D
-10.3%
1Y
-16.3%
OPTI
CA$5.80
Optimi Health
7D
-18.3%
1Y
17.2%
CRON
CA$3.88
Cronos Group
7D
0.8%
1Y
48.7%
Narrative Update • Jun 14

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.
NVRS
CA$1.74
Noveris Health Sciences
7D
3.0%
1Y
596.0%
GTII
CA$10.47
Green Thumb Industries
7D
-3.2%
1Y
44.2%
Narrative Update • Jun 11

GTII: Rescheduling Order And Buybacks Will Support Higher Future Share Price

Analysts have increased their CA$ fair value estimate for Green Thumb Industries from CA$18.08 to CA$20.31, citing higher price targets and optimism around recent regulatory developments, including views that partial cannabis rescheduling could be extremely favorable for the sector. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher CA$ fair value estimate and raised price targets as a sign that recent regulatory developments are being reflected more fully in valuation assumptions.
CWEB
CA$0.45
Charlotte's Web Holdings
7D
6.0%
1Y
242.3%
GUD
CA$9.37
Knight Therapeutics
7D
0.5%
1Y
63.0%
Narrative Update • Jun 05

GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing

Analysts have revised the fair value estimate for Knight Therapeutics from about CA$12.00 to roughly CA$11.65, reflecting updated assumptions on revenue growth, profit margins and a higher future P/E multiple. Recent Street research also includes higher CA$ price targets and renewed positive coverage.